A Natural History Study of Aspartylglucosaminuria

Lysosomal Storage Diseases Clinical Trial

— AGU  

Official title:

A Natural History Study of Aspartylglucosaminuria

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03853876
• Other study ID #: AGU-100
• Status: Terminated
• Start date: April 18, 2019
• Est. completion date: March 17, 2022

Study information

• Verified date: April 2022
• Source: Neurogene Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Aspartylglucosaminuria (AGU) is a rare neurodegenerative lysosomal storage disease (LSD) characterized by developmental delay, psychomotor regression, worsening intellectual disability, gait disturbance and, ultimately, premature death, and has no available treatments.

The purpose of this study is to investigate the clinical characteristics and natural clinical progression of symptoms in individuals with AGU. This natural history study is important to better understand disease course to be able to determine clinically meaningful outcome measures for use in future clinical trials.

Description:

Lysosomal storage disorders (LSDs) are a group of inherited metabolic diseases caused by a genetic mutation resulting in deficiency or absence of a critical enzyme, leading to the accumulation of toxic deposits in cells across multiple organ systems.

Aspartylglucosaminuria (AGU) is a rare, neurodegenerative, LSD, caused by a deficiency of the aspartylglucosaminidase (AGA) enzyme, which leads to toxic accumulation of aspartylglucosamine and subsequent cellular dysfunction. AGU has been most commonly reported in people of Finnish and Nordic descent, but is present across ethnicities and is typically misdiagnosed or undiagnosed.

Aspartylglucosaminuria (AGU) is characterized by developmental delay and intellectual disability that worsens with age. Early disease is characterized by increased frequency of bacterial ear infections, recurrent ear tube placement, intestinal dysfunction, disruptive sleep patterns, skeletal abnormalities, and gait disturbances, among others. Individuals progressively lose motor and cognitive skills, develop behavioral/emotional lability and their risk of seizures increases with age. People with AGU have a shortened life span.

No prospective natural history study for AGU has been reported. This study aims to prospectively investigate the natural history of AGU, and concurrently to identify potential outcome measures that could be used in future clinical trials. No investigational product will be provided in the study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 8
• Est. completion date: March 17, 2022
• Est. primary completion date: October 15, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Participants must have a diagnosis of AGU based on clinical presentation and genetic testing (known or suspected pathogenic mutation in AGA gene).

Exclusion Criteria:

• Patients unable to travel to UT Southwestern Medical Center and Children's Health Dallas will not be enrolled in the prospective natural history study collecting standardized clinical data; however, with participant consent, medical records will be obtained, reviewed, and recorded in the natural history database over time.

Related Conditions & MeSH terms

• Aspartylglucosamidase (AGA) Deficiency
• Aspartylglucosaminuria
• Lysosomal Storage Diseases

Locations

Country	Name	City	State
United States	University of Texas Southwestern	Dallas	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Neurogene Inc.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Neuropsychological Testing	Participants will undergo a standardized neuropsychological evaluation every 6-12 months, depending upon the assessments as follows: Global Cognitive: Leiter International Performance Scale, 3rd Ed, Reynolds Intellectual Assessment Scales, 2nd Ed, Mullen Scales of Early Learning; Emotional: Aberrant Behavior Checklist, 2nd Ed, Behavior Assessment System for Children, 3rd Ed; Behavioral functioning: Aberrant Behavior Checklist, 2nd Ed, Behavior Assessment System for Children, 3rd Ed	5 years
Primary	Ophthalmological Evaluation	Participants will undergo an ophthalmological assessment every 6 months to better characterize the involvement of the eye in AGU.	5 years
Primary	Visual Evoked Potential (VEP)	Participants will undergo a VEP test every 6 months to evaluate electrical signal transmission through the visual pathway from the retina to the visual cortex.	5 years
Primary	Brainstem Auditory Evoked Response (BAER)	Participants will undergo a BAER test every 6 months to evaluate electrical signal transmission from the 8th cranial nerve to the brainstem and the cortex in response to certain tones.	5 years
Primary	Magnetic Resonance Imaging (MRI)/Magnetic Resonance Spectroscopy (MRS)	An MRI scan of the brain will be performed annually to characterize the structural abnormalities associated with AGU. MRS will be performed on regions of interest in the brain.	5 years
Secondary	Adaptive functioning: Vineland Adaptive Behavior Scales, 3rd Ed	Participants will undergo a standardized neuropsychological evaluation every 6-12 months	5 years
Secondary	Language: Expressive One-Word Picture Vocabulary Test, 4th Ed, Receptive One-Word Picture Vocabulary Test, 4th Ed, NEPSY, 2nd Ed	Participants will undergo a standardized neuropsychological evaluation every 6-12 months	5 years
Secondary	Motor: NIH Toolbox Early Childhood Motor Battery or NIH Toolbox Motor Battery, 6 Minute Walk Test, Beery-Buktenica Development	Participants will undergo a standardized neuropsychological evaluation every 6-12 months	5 years